160 related articles for article (PubMed ID: 25605848)
1. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy.
Srikanthan A; Tran B; Beausoleil M; Jewett MA; Hamilton RJ; Sturgeon JF; O'Malley M; Anson-Cartwright L; Chung PW; Warde PR; Winquist E; Moore MJ; Amir E; Bedard PL
J Clin Oncol; 2015 Feb; 33(6):582-7. PubMed ID: 25605848
[TBL] [Abstract][Full Text] [Related]
2. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).
Tran B; Ruiz-Morales JM; Gonzalez-Billalabeitia E; Patrikidou A; Amir E; Seidel C; Bokemeyer C; Fankhauser C; Hermanns T; Rumyantsev A; Tryakin A; Brito M; Fléchon A; Kwan EM; Cheng T; Castellano D; Garcia Del Muro X; Hamid AA; Ottaviano M; Palmieri G; Kitson R; Reid A; Heng DYC; Bedard PL
Cancer Med; 2020 Jan; 9(1):116-124. PubMed ID: 31715650
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.
Bezan A; Posch F; Ploner F; Bauernhofer T; Pichler M; Szkandera J; Hutterer GC; Pummer K; Gary T; Samonigg H; Beyer J; Winder T; Hermanns T; Fankhauser CD; Gerger A; Stotz M
PLoS One; 2017; 12(4):e0176283. PubMed ID: 28430804
[TBL] [Abstract][Full Text] [Related]
4. Primary Thromboprophylaxis and the Risk of Venous Thromboembolic Events in Patients With Testicular Germ Cell Tumors Treated With Cisplatinum-Based Chemotherapy.
Terbuch A; Walser G; Stotz M; Gerger A; Posch F; Bauernhofer T
Clin Genitourin Cancer; 2023 Feb; 21(1):24-31. PubMed ID: 36400695
[TBL] [Abstract][Full Text] [Related]
5. Predictors of venous thromboembolism development before and during chemotherapy for advanced germ cell tumor.
Nitta S; Kawai K; Kimura T; Kawahara T; Kandori S; Hoshi A; Kojima T; Nishiyama H
Jpn J Clin Oncol; 2020 Mar; 50(3):338-343. PubMed ID: 32037439
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
Gonzalez-Billalabeitia E; Castellano D; Sobrevilla N; Guma J; Hervas D; Luengo MI; Aparicio J; Sanchez-Muñoz A; Mellado B; Saenz A; Valverde C; Fernandez A; Margeli M; Duran I; Fernandez S; Sastre J; Ros S; Maroto P; Manneh R; Cerezuela P; Carmona-Bayonas A; Ayala de la Peña F; Luis Aguilar J; Rivera S; García Del Muro X; Germà-Lluch JR;
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122896
[TBL] [Abstract][Full Text] [Related]
7. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
[TBL] [Abstract][Full Text] [Related]
8. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
[TBL] [Abstract][Full Text] [Related]
9. Predictive Factors for Developing Venous Thrombosis during Cisplatin-Based Chemotherapy in Testicular Cancer.
Heidegger I; Porres D; Veek N; Heidenreich A; Pfister D
Urol Int; 2017; 99(1):104-109. PubMed ID: 28514776
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
11. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
Khorana AA; Dalal M; Lin J; Connolly GC
Cancer; 2013 Feb; 119(3):648-55. PubMed ID: 22893596
[TBL] [Abstract][Full Text] [Related]
12. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
[TBL] [Abstract][Full Text] [Related]
13. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
14. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients.
Ferroni P; Martini F; Portarena I; Massimiani G; Riondino S; La Farina F; Mariotti S; Guadagni F; Roselli M
Clin Lung Cancer; 2012 Nov; 13(6):482-7. PubMed ID: 22591606
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy.
Honecker F; Koychev D; Luhmann AD; Langer F; Dieckmann KP; Bokemeyer C; Oechsle K
Onkologie; 2013; 36(11):663-8. PubMed ID: 24192771
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy.
Brown LC; Robinson M; McCormack M; Steuerwald N; Symanowski J; Sha W; Bose R; Neelands B; Akinyelu T; Livasy C; Li W; Haynes N; Hamilton A; Smith M; Clark PE; Patel J; Burgess EF
Clin Genitourin Cancer; 2024 Jun; 22(3):102086. PubMed ID: 38697880
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study.
Zahir MN; Shaikh Q; Shabbir-Moosajee M; Jabbar AA
BMC Cancer; 2017 Jan; 17(1):57. PubMed ID: 28093087
[TBL] [Abstract][Full Text] [Related]
18. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
[TBL] [Abstract][Full Text] [Related]
19. PO-04 - A new genetic risk score for predicting venous thromboembolic events in cancer patients receiving chemotherapy.
Martín AJ; Ziyatdinov A; Rubio VC; Olmos VP; Huerta BM; Rodríguez JC; Fernández MS; de Castro EM; Caro RL; Fernández JM
Thromb Res; 2016 Apr; 140 Suppl 1():S177-8. PubMed ID: 27161691
[TBL] [Abstract][Full Text] [Related]
20. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
